Introduction
Metachromatic leukodystrophy: an overview of current and prospective treatments
Place of HSCT in treatment of childhood AML
Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors
Haematopoietic SCT for children and adolescents with relapsed and refractory Hodgkin's lymphoma
Allogeneic or haploidentical HSCT for refractory or relapsed solid tumors in children: toward a neuroblastoma model
Monitoring of post-transplant remission of childhood malignancies: is there a standard?
Where should adolescents with ALL be treated?
Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT
The use of reduced-intensity stem cell transplantation in haemophagocytic lymphohistiocytosis and Langerhans cell histiocytosis
HSCT for Fanconi anemia in children: factors that influence early and late results
Haploidentical SCT in children: an update and future perspectives
Potential role of mesenchymal stromal cells in pediatric hematopoietic SCT
Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT
Role of HLA in hematopoietic SCT
Prevention of infectious complications in pediatric HSCT
JACIE accreditation in paediatric haemopoietic SCT
Quality of life and ethical and legal dilemmas in children during and after hematopoietic SCT procedure
Assessing the risk of transplant-related complications and individually tailoring the HSCT procedure in children and adolescents-is it possible?
Risk-adapted procedures for HSCT from alternative donor in children with severe aplastic anaemia
Innovative approaches to treat steroid-resistant or steroid refractory GVHD
04
05
09
14
15
16
19
27
28
35
39
40
45
46
47
51
52
53
56
57
58
P01
P02
P03
P04
P05
P06
P07
P08
P09
P10
P11
P12
P16
P17
P18
P19
P20
P21
P22
P23
P24
P25
P26
P27
P28
P29
P30
P31
P32
P33
P34
P35
P36
P37
P39
P40
P41
P42
P43
P44
P45
P46